Vancouver, B.C., March 21, 2018 – MYM Nutraceuticals Inc., (CSE: MYM) (the “Company” or “MYM”) announces the granting of 75,000 stock options for Chief Science Officer (CSO), Dr. Charith Adkar.

Dr. Adkar completed his PhD in Plant Biology and Crop Production from the University of Milano, Italy with the specialization in Molecular Plant Pathology. He completed his postdoctoral studies at Hirosaki University, Japan and Université de Sherbrooke, Canada. His areas of expertise include Plant Science, Biotechnology, Microbiology, Molecular host-pathogen interactions and Bioinformatics. His work has featured in more than 45 scientific publications. He has received several prestigious fellowships such as: Japan Society for Promotion of Sciences (JSPS), Postdoctoral Fellowships for Foreign Researchers, Fonds Québécois de la recherche sur la nature et les technologies (FQRNT), Quebec, Canada. He also received the best research article award from the Phytopathological Society of Japan and Journal of General plant pathology for Research Article of the Year 2015.

Dr. Adkar will manage MYM’s scientific, research and technological operations. He will work primarily at the Laval and Weedon production facilities.

“We’re extremely pleased to welcome Dr. Charith Adkar to the MYM team,” said Rob Gietl, CEO of MYM. “Dr. Adkar will be instrumental in leading MYM to be a global innovator in the science and technology of medicinal cannabis. His proven track record and research in plant biology and crop production will ensure that MYM will be on the cutting edge of cannabis plant discovery and research.”

Mr. Adkar will be granted options to purchase 75,000 common shares of the Company in accordance with the Company’s stock option plan. The options are exercisable at a price of $2.88 per share.  25,000 options will vest every six months from February 23, 2018. Each option will expire one year after its vesting date.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products.  MYM has two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a partner in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD

Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca

Investor Relations
Terry Brown
1.855.696.2261
terry@mymarijuana.ca